|
Hodgkin Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using WebHERV, we predicted putative candidates of active HERV-like sequences in Hodgkin lymphoma (HL) cell lines, validated one of them by a modified SMART (switching mechanism at 5' end of RNA template) technique, and identified a new alternative transcription start site for cytochrome P450, family 4, subfamily Z, polypeptide 1 (CYP4Z1).
|
30455669 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using WebHERV, we predicted putative candidates of active HERV-like sequences in Hodgkin lymphoma (HL) cell lines, validated one of them by a modified SMART (switching mechanism at 5' end of RNA template) technique, and identified a new alternative transcription start site for cytochrome P450, family 4, subfamily Z, polypeptide 1 (CYP4Z1).
|
30455669 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using WebHERV, we predicted putative candidates of active HERV-like sequences in Hodgkin lymphoma (HL) cell lines, validated one of them by a modified SMART (switching mechanism at 5' end of RNA template) technique, and identified a new alternative transcription start site for cytochrome P450, family 4, subfamily Z, polypeptide 1 (CYP4Z1).
|
30455669 |
2018 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, the main challenge for a CYP4Z1-based prodrug strategy (CBPS) for the treatment of breast cancer (and possibly other CYP4Z1-positive malignancies) is the identification of candidate prodrugs that can be activated by this enzyme.
|
28176668 |
2017 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
CYP4Z1 is of interest because it is strongly overexpressed both in breast cancer cells and in breast cancer metastases; however, current knowledge about its catalytic properties is very limited.
|
28951277 |
2017 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
CYP4Z1 is of interest because it is strongly overexpressed both in breast cancer cells and in breast cancer metastases; however, current knowledge about its catalytic properties is very limited.
|
28951277 |
2017 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our data demonstrates that the ceRNET between CYP4Z1 and pseudogene CYP4Z2P acts as a sub-ceRNET to promote CDK3 expression in ER-positive breast cancer and is a potential therapeutic target for treatment of tamoxifen-resistant breast cancer.
|
26980484 |
2016 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CYP4Z1 overexpression significantly increased tumor weight and microvessel density by 2.6-fold and 1.9-fold in human tumor xenograft models, respectively.
|
22841774 |
2012 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, the precise role of CYP4Z1 in tumor progression is unknown.
|
22841774 |
2012 |
|
Tumor Angiogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
|
31655919 |
2020 |
|
Tumor Angiogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Increased CYP4Z2P- and CYP4Z1-3'UTR expression promotes tumor angiogenesis in breast cancer partly via miRNA-dependent activation of PI3K/Akt and ERK1/2.
|
25701119 |
2015 |
|
Tumor Angiogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Here, we demonstrate that CYP4Z1 overexpression promotes tumor angiogenesis and growth in breast cancer.
|
22841774 |
2012 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
|
31655919 |
2020 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The expression of CYP4Z1 and the pseudogene CYP4Z2P has been shown to be specifically increased in breast cancer by our group and others.
|
30832689 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that the ceRNET between CYP4Z1 and pseudogene CYP4Z2P acts as a sub-ceRNET for hTERT and, thus, inhibits breast cancer apoptosis.
|
28236635 |
2017 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
CYP4Z1 is of interest because it is strongly overexpressed both in breast cancer cells and in breast cancer metastases; however, current knowledge about its catalytic properties is very limited.
|
28951277 |
2017 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
However, the main challenge for a CYP4Z1-based prodrug strategy (CBPS) for the treatment of breast cancer (and possibly other CYP4Z1-positive malignancies) is the identification of candidate prodrugs that can be activated by this enzyme.
|
28176668 |
2017 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
The ceRNET between CYP4Z1 and pseudogene CYP4Z2P has been revealed to promote breast cancer angiogenesis.
|
26980484 |
2016 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Therefore, those preliminary data suggest that CYP4Z1 3'UTR could inhibit the migration and EMT of breast cancer cells via acting as a ceRNA for E-cadherin.
|
27520371 |
2016 |
|
Malignant neoplasm of breast
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the roles of the pseudogene CYP4Z2P-3'UTR and functional gene CYP4Z1-3'UTR in breast cancer angiogenesis process.
|
25701119 |
2015 |
|
Malignant neoplasm of breast
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that CYP4Z1 overexpression promotes tumor angiogenesis and growth in breast cancer.
|
22841774 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
|
31655919 |
2020 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CYP4Z1 and the pseudogene CYP4Z2P has been shown to be specifically increased in breast cancer by our group and others.
|
30832689 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP4Z1 is of interest because it is strongly overexpressed both in breast cancer cells and in breast cancer metastases; however, current knowledge about its catalytic properties is very limited.
|
28951277 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that the ceRNET between CYP4Z1 and pseudogene CYP4Z2P acts as a sub-ceRNET for hTERT and, thus, inhibits breast cancer apoptosis.
|
28236635 |
2017 |